Therapeutic Applications and Pipeline Developments
Ustekinumab, an interleukin-12 and interleukin-23 inhibitor, has been a breakthrough treatment for a variety of immune-mediated diseases. Its primary indications include moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The drug's efficacy and favorable safety profile have made it a preferred option for many patients. Recent pipeline developments are focusing on expanding its use, including new formulations and indications for pediatric patients. This continued investment in research and development by both originator and biosimilar companies highlights the ongoing importance of ustekinumab in clinical practice.
Learn about Ustekinumab's applications in inflammatory diseases
FAQs:
For which diseases is ustekinumab primarily used? Ustekinumab is primarily used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Are there any new indications for ustekinumab in development? The pipeline includes research into expanding its use, such as for pediatric indications and potentially other immune-mediated disorders.